Posted AT 4:07 AM EST on 30/10/06
Caution emerges over inhalable insulin
The air is leaking out of what was supposed to be the next big thing in the treatment of diabetes: inhalable insulin."While inhalable insulins will see a reasonable level of uptake, they aren't the surefire blockbuster they were hyped to be," says a new study by British market research firm Datamonitor PLC. It points out that the new treatment isn't significantly better than existing therapies, is expensive and its long-term safety in the lungs is unknown.
The full text of this article has 574 words.
To continue reading this article, you will need to purchase this article.
Already have a member account? Login now
Pay-Per-View Offers To read the complete article, select one of the following options
Purchasing from globeandmail.com is quick and secure.
